Rosenberg (11) . Analyses of thrombin concentrations were performed by the modified National Institutes of Health (NIH) procedure (12) described by Mann et al. (13) .
Coagulation tests were performed by published methods (14) . The appearance of the anticoagulant material throughout the different steps of the isolation and purification procedures were monitored by the thrombin time using crude bovine thrombin reconstituted to yield a normal thrombin time of [16] [17] [18] s in the absence of added inhibitor. As a substrate, 50 ,ul ofa 0.15 M NaCl solution in which the unknown material was dissolved was added to 150 ,ul of normal pool of fresh plasma collected in oxalate; as a control, 50 ,ul of 0. 15 M NaCl was added to 150 ,ul of normal plasma. The anticoagulant activity of the material was measured against a standard curve prepared with increasing dilutions of beef lung heparin with 0.15 M NaCl as a diluent. Because of the variation of the thrombin solution from day to day, such a standard curve was freshly plotted every time an assay ofthe anticoagulant activity was to be done.
Proteolytic digestion was accomplished by incubating the thawed patient plasma, freshly collected in acid citrate dextrose and stored at -700C, or the isolated proteoglycan from platelet Factor 4 (PF4)2-Sepharose column, with pronase (3 mg/100 ml) for 48 h at 450C. At the end ofthis period, solid trichloroacetic acid was added to 5% (wt/vol) and incubation continued for 2 h at 40C. The supernate from this as well as two washes of the precipitate with deionized water were exhaustively dialyzed against the water and lyophilized.
PF4 was coupled to aminohexyl Sepharose 4B in the following manner: to 1 ml of packed resin was added 2.5 ml human PF4 (2.6 mg/ml) in 0.5 M NaCl, pH 5.5, 22°C. 20 mg of solid water-soluble carbodiimide was then added with stirring and the pH maintained at 4.5-5.5 by the addition of dilute HCl over a period of 1 h. Stirring was then continued overnight at 22°C. The resin was then filtered, washed with 100 ml of 0.02 M Tris-HCl, 1.5 M sodium chloride, pH 7.4. Resin was then washed in 0.02 M Tris-HCl, 0.15 M NaCl, pH 7.4 for storage or further use.
Molecular weight estimations were performed with the high speed sedimentation equilibrium technique (15) using a Beckman model E analytical centrifuge (Beckman Instruments, Inc., Fullerton, Calif.). No gross curvature was observed in high speed sedimentation equilibrium experiments. Therefore, weight average molecular weights (NMw) were calculated from direct analysis of the slope of plots of log fringe displacement (lnc) vs. radial distance squared (r2) using the equation:
The Z average molecular weights were calculated by extrapolation of Mwr, the weight average molecular weight at any point r to the cell bottom. A value of 0.53 cm3/g (16) Uronic acid content was measured by the carbazole reaction according to Bitter and Muir (17) . Gel electrophoretic analyses 2Abbreviationt used itl this paper: PF4, platelet Factor 4.
of acid mucopolysaccharide were performed according to the procedure of Homer (18) in lithium acetate buffer and 0.6 or 1.2% agarose gels. Staining was accomplished using toluidine blue 0. Antithrombin III cofactor activitv of the isolated anticoagulant was evaluated with purified coomponents. Solutions of the isolated inhibitor at concentrations equivalent to 0.66 U heparin/ml (deten-nined from thrombin-time assays onl nlorimnal human plasma) were incubated at 220C in 0.02 M Tris-HCl, 0.15 NI NaCl, pH 7.4 with bovine antithrombin III (2.44 ,utM) and human a-thrombin (0.856 KLM). At regular intervals after the addition of thrombin aliquots of the reaction mixture were withdrawn and assayed for residual thrombin-catalyzed clotting activitv according to the NIH procedure (12) as modified by Mann et al. (13) . Control experiments were also performedl using an eqtuivalent amount of commercial heparin in place of the isolated anticoagulant. In some instances human PF4 at a final concentration of0.14 mg/!lll was included to compare the neutralization of the heparin-like cofactor activitv of the patient-derived inhibitor to the neutralizationi of commercial heparin.
The patient's leukocvtes, obtained by leukophoresis, were pelleted by centrifugation at 800 g for 8 min. Cells were then prepared for either short-tenrm culture or homogenization. For short-term cultures, the cells were resuspended in RPMI 1640 medium and cultured in Marbrook vessels (19) as described by Katzmann (20) . Cell pellets were homogenized in a pestle tissue grinder maintained at 0°C. Nuclei and cellular debris were removed by centrifugation at 1,000 g for 10 min. The supernate of the short-term leukocyte culture did not possess anticoagulant activity, nor did the extracts of homogenized cells.
Case report. The patient was a 68-yr-old female with a 10-mo history of multiple myeloma (imunuoglobulin [ Laboratorv studies: hemoglobini 10.2 gIlO0 ml, leukocvtes 29,500/mm3 with 63% plasma cells; platelet count 12,000/ mnm3; calcium 15 rng/100 ml, uric acid 6.6 mg/100 ml, and creatinine 7.2 mg/100 ml. Total serum protein 7.2 g/100 ml with 4.5 g/100 ml albumin and 0.28 g/100 ml alpha 1, 0.92 g/ 100 ml alpha 2, 1.4 g/100 ml beta, and 0.82 g/100 ml gammlla globulin. The IgA was 4.9 mg/ml, IgM 0.15 mg/mIl, and IgG 4.0 mg/mIl. The urine was positive for Bence Jones protein and showed a monoclonal kappa spike on immunoelectrophoresis. Bone marrow aspiration showed over 90% abnormal plasma cells. No mast cells were seen. Coagulation studies are presented in Table I .
RESULTS
The chromatographic separation of the anticoagulant material present in the patient's plasma on PF4-Sepharose is presented in Fig. IA , whereas the chromatographic behavior of beef lung heparinized-humani acid citrate dextrose plasma used as a control is presented in Fig. lB . In each case, 5 ml of the anticoagulated plasma was allowed to percolate through -3 ml of PF4-Sepharose. The material not bound in each case represents most of the plasma protein present in the original samples. The plasma used in the heparin control was anticoagulated by the addition of 250 U of beef lung heparin, and before application to the column had a clot time of > 100 s. The initial fractions from this column had a thrombin clot time of 22.6 s. Similarly, patient plasma, which before application to the column had a plasma thrombin clot time of > 100 s, exhibited a thrombin clot time for the initial fractions of 25.5 s. Thus, in both the experimental and control PF4-Sepharose columlln, the anticoagulant activity was removed on the column, and the clottability of the plasma coming through the colunmn was restored. Subsequent elution ofthe column after washing with 0.5 M sodium chloride, was accomplished with 0.75 M salt. The anticoagulant activity eluted from each column is expressed in terms of the fraction of the quantity of anticoagulant applied to the column based upon the heparin assay described in Methods. Under this set of conditions, anticoagulanit activity, some protein (as exhibited by absorbanice at 280 nm), and uronic acid were elaborated from both the chromatography ofthe patient plasma and chromatography of the heparinized normal plasma. Subsequent elution of both columns with 1.5 M sodium chloride resulted in the elution of a small amount of additional anticoagulant activity from the patient's plasma aind the larger fraction of anticoagulant activity from the column to which the heparinized normal plasma was applied. The appearance of two peaks from each column is a reproducible occurrence that does not appear to be related to individual heparin components in each sample, but rather to anomalous columiin behavior, in that reapplication of either of the components eluted at 0.75 M or 1.5 M results in a similar chromatographic pattern; that is, two peaks on elution. Most likely this anomalous behavior is a reflection of heterogenous bindinig of PF4 to the agarose support rather than heterogeneity in the anticoagulant activity applied to the column.
The amount of' anticoagulant material present in the patient's plasma was about 30 gsg/ml, based upoIn recoveries from the PF4-Sepharose columlln.
For the columnn to which the patient's plasimia was applied, the comiiponents eluted at 0.75 -M salt cointained, in addition to anticoagulant activity and tironic acid, sonme proteinaceous comiiponients. In addition, immunodiffusioni experiments revealed the presence oftrace amnounts of human antithrombin III in the comilponents eluted in this fraction, whereas sodiu-m dodecyl suilfate gel electrophoretic analysis showed fainit an-iotunts of a variety of proteins associated with this peak. The components eluted in the 0.75 M fraction fromn the patient's plasma were pooled and suibjecte(d to chromatography on Bio-Rad P-150. Anticoagulanit activity was eluted in the void volume of this column. The miiaterial retained its absorbance at 280 nm, suiggestinig the continued presence of protein.
To coiipare the patient-derived ainticoagulanit with commercial hepariin, the 0.75 M fraction was subjected to proniase digestion and trichloroacetic acid precipitation to remove the protein comlponenit(s). These steps were taken because commlllercial heparin is obtaine(d onily after rigorous proteolytic and chemical digestioni of the animiial tissue fronm which the polysaccharide is derived. After this treatinent all absorbance at 280 nIn was lost from the anticoagulanit preparation, whereas the anticoagulant activity was completely recoveredl. A comparison of the gel filtration behavior ofthis material with comnmercial heparin, usinig 10% agarose, is presented in Fig. 2 . In contrast with commnercial heparin, the patient-derived aniticoagulanit peptidoglycani is excluded from a 10% agarose column and appears to be of substantially larger size than commiiiiercial beef lulng heparin.
The isolated peptidoglyean was subjected to agarose gel electrophoretic analysis in lithiumii acetate, pH 3, to compare its relative electrophoretic mobility to that of other known sulfate(d polysacchari(le standards. The electrophoretic miobility of the acid mulcopolysaccharides are functions of their charge density, and mnost of these can be distinguished electrophoretically. Represented in Fig. 3 is a photograph of agarose gel electroplhoretograms of reference stanidard acid mucopolysaccharides and the anticoaguilant peptidoglycan derived from the patient's plasma. Reference standard acid miiucopolysaccharides are present in gels B through H. The dyefront marker, amaranth, is in gel K. The patient-derived anticoagulant is present in gels A, I, and J; as the isolatedi material (gel A), as the isolated material mixed with heparin (gel I), and the isolated material mixed with heparan sulfate (gel J). It canl be seen that the patient-derived peptidoglycan ainticoagulant is electrophoretically homogeneous in this system and is eintirely distinguished from heparini and five of the other sulfated polysaccharide reference standards used for comparison. Functioinal assays of the relative anticoagulaint potency of the patient-derived peptidoglycani were coinducted by comiipariing its effects to that of commiiiiercial heparini oIn a plasmiia-thromiibini clot timiie. The patienit-derivedl anticoagulanit had a specific activity of -8 U/miig, which is substantially less thani the specific activity of the commlllercial beef luIng heparin, which has a specific activity of -120 U/miig.
The niatture of the initeraction of the patient-derived ainticoagtulanit peptidoglycan with antithrombin III, thrombin, and PF4 vere compared to that of beef lunig heparin. The results of these experimeints are presented in Fig. 5 oglycan anticoagulant, antithrombin III, and thrombin, equivalent rates of inactivation for thrombin were observed. These rates obtained after neutralization of heparin and heparin-like anticoagulant are experimentally equivalent to the rate of neutralization of the equivalent amount of thrombin by the equivalent amount ofantithrombin III alone (Fig. 5, open triangles) . It should be noted here that the rate observed and presented for Fig. 5 Table IV . (21) (22) (23) . The molecular weight ofthe reference stanclardl heparan sulfate used for electrophoretic and chromatographic comparisons can be estimated to be in the range of 30,000-40,000 based upon intrinsic viscosity data' supplied with the material. Both of these materials were isolated with harsh chemical extraction procedures and proteolytic digestion of the animal tissue. In contrast, macromolecular heparin has been observed on more gentle extraction of cultures of mast cells (24, 25) , and from rat skin (26, 27) . In these cases, the major heparin fraction obtained was resistent to protease digestion but could be reduced in size by alkaline hydrolysis, oxidative-reductive depolyimerization with ascorbic acid, or by cleavage by heparinases. The products obtained by the chemical treatments had mol wt near 40,000, whereas the enzymatic digestion products had a mol wt of about 14,500.
Heparan sulfates are found in a variety of tissues including the aorta (28, 29) , and apparently are susceptible to change with both age (30) and disease (31) , including cellular transformation (32) (33) (34) . In contrast to heparin, which appears to be a complex macromolecular polysaccharide structure with additional protein attached, heparan sulfate appears to be a proteoglycan with a peptide backbone to which a series of polysaccharide chains is connected. Jansson and Lindahl (35) reported the isolation of a heparan sulfate proteoglycan fromn aorta that had an apparent mol wt of 70,000 and could be cleavedl to produce polysaccharide chains with a mol wt of 10,000. Chiarugi and(l Urbano (36) reported the isolation of a heparan sulfate proteoglycani for normiial and Rotis sarcoma virus transformed baby hampster kidney cells which was -40% protein and had a mol wt of 130,000, somewhat similar to the value obtained for our material.
Circulating anticoagulants have been known to occur in a broad variety of conditions. Some of these anticoagulants, such as the lupus anticoagulant, cause an immediate inhibition of the coagulation mechanism whereas others are directed against specific coagulation factors, particularly factor VIII (37) . In multiple myeloma, however, specific abnormalities in the clotting mechanisms have not frequently been characterized. Prolongation of prothrombin and partial thromboplastin times have generally been attributed to nonspecific interference of the monoclonal proteins, although in certain instances specific coagulation factor antibodies have been elaborated in myelomna (1) . In several studies (4, 5, 38) , an antithrombin role has been assigned to a protein in the plasma which may, or may not, have been the monoclonial immunoglobulini molecule. In two studies (39, 40) heparin-like activity for an anticoagulant was suggested but fu-rther analyses were not conducted to specifically identify the nature of the anticoagulant activity. In the patient whose anticoagulant is the subject of this investigation, the anticoagulant material appears to have no specific relationship to the immunoglobulin elaborated by the myeloma cell line, and, in fact, the patient's disease was in remission and IgA at a normal level when the spontaneously occurring anticoagulant activity developed. The observation of a circulating heparani sulfate proteoglyean in this patient is provocative in view of reports suggesting differences with respect to heparan sulf:ate in mucopolysaccharide components after cell transformation (32) (33) (34) . Although this particular patient had a plasma cell leukemia, the anticoagulant activity was not elaborated in short-term cultures of her peripheral leukocytes, nor was it present in the extracts of homogenates of the cultured cells. Thus, although this anticoagulant molecule was generated in the blood ofthe individual suffering from plasma cell leukemia, no direct connections between the disease state and the anticoagulant molecule can be identified.
Two potential routes by which the anticoagulant molecule may have appeared in the plasma appear worthy of some speculation. These are: (a) that the anticoagulant molecule is a normal constituent of plasma, ordinarily present only at very low concentrations, which was released 4t a greater rate as a consequenice of the disease state; and (b) that tissue damage secondary to the primary disease state has led to the release of the proteoglycan. Heparan sulfate and related substances have been reported to be produced by endothelial cells in culture (6); in addition, Muller et al. (41) have reported a heparin-like inhibitor in the blood of the newborn, and it is conceivable that the anticoagulant described in the present work is related to these materials.
